TW239132B - - Google Patents

Info

Publication number
TW239132B
TW239132B TW082104624A TW82104624A TW239132B TW 239132 B TW239132 B TW 239132B TW 082104624 A TW082104624 A TW 082104624A TW 82104624 A TW82104624 A TW 82104624A TW 239132 B TW239132 B TW 239132B
Authority
TW
Taiwan
Application number
TW082104624A
Other languages
Chinese (zh)
Inventor
Kra Mer Thomas
Muller-Gliemann Matthias
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of TW239132B publication Critical patent/TW239132B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW082104624A 1992-06-26 1993-06-11 TW239132B (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4220983A DE4220983A1 (de) 1992-06-26 1992-06-26 Imidazolyl-substituierte Phenylpropion- und -zimtsäurederivate

Publications (1)

Publication Number Publication Date
TW239132B true TW239132B (OSRAM) 1995-01-21

Family

ID=6461888

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082104624A TW239132B (OSRAM) 1992-06-26 1993-06-11

Country Status (17)

Country Link
US (1) US5414008A (OSRAM)
EP (1) EP0578002A1 (OSRAM)
JP (1) JPH0665209A (OSRAM)
KR (1) KR940000434A (OSRAM)
CN (1) CN1082041A (OSRAM)
AU (1) AU4006393A (OSRAM)
CA (1) CA2099068A1 (OSRAM)
CZ (1) CZ117493A3 (OSRAM)
DE (1) DE4220983A1 (OSRAM)
FI (1) FI932953A7 (OSRAM)
HU (1) HUT65190A (OSRAM)
IL (1) IL106108A0 (OSRAM)
MX (1) MX9303600A (OSRAM)
NO (1) NO932132L (OSRAM)
SK (1) SK66793A3 (OSRAM)
TW (1) TW239132B (OSRAM)
ZA (1) ZA934584B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4214537B2 (ja) * 1996-08-12 2009-01-28 セルジーン コーポレーション 新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
US7165676B2 (en) * 2002-04-19 2007-01-23 Smurfit-Stone Container Enterprises, Inc. Heat seal blister package having improved moisture vapor transmission barrier and method for forming same
US7470723B2 (en) * 2003-03-05 2008-12-30 Celgene Corporation Diphenylethylene compounds and uses thereof
BRPI0408005A (pt) * 2003-03-05 2006-02-14 Celgene Corp composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor
EP1794139A2 (en) * 2004-09-03 2007-06-13 Celgene Corporation Substituted heterocyclic compounds and uses thereof
US20080064729A1 (en) * 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
PH12017502255B1 (en) * 2015-06-15 2022-07-22 Astex Therapeutics Ltd Nrf2 regulators
WO2023274257A1 (zh) * 2021-07-01 2023-01-05 诸葛国琴 一种咪唑类化合物、其中间体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55313A (en) * 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3130254A1 (de) * 1981-07-31 1983-02-17 A. Nattermann & Cie GmbH, 5000 Köln (omega)-(4-((omega)'-(1-imidazolyl)-alkyl)-phenyl)-(omega)-oxo-alkancarbonsaeuren und deren derivae, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3424944A1 (de) * 1984-07-06 1986-02-06 Hoechst Ag, 6230 Frankfurt Neue imidazolyverbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
DE3800785A1 (de) * 1988-01-09 1989-07-20 Hoechst Ag Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5164407A (en) * 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
US5183810A (en) * 1990-02-13 1993-02-02 Merck & Co., Inc. Imidazole angiotensin II antagonists incorporating a substituted benzyl element
JP2626167B2 (ja) * 1990-05-18 1997-07-02 日産自動車株式会社 四輪駆動車のトランスファー装置

Also Published As

Publication number Publication date
JPH0665209A (ja) 1994-03-08
KR940000434A (ko) 1994-01-03
DE4220983A1 (de) 1994-01-05
CN1082041A (zh) 1994-02-16
FI932953A0 (fi) 1993-06-24
SK66793A3 (en) 1994-02-02
NO932132L (no) 1993-12-27
NO932132D0 (no) 1993-06-10
CA2099068A1 (en) 1993-12-27
MX9303600A (es) 1993-12-01
AU4006393A (en) 1994-01-06
US5414008A (en) 1995-05-09
FI932953A7 (fi) 1993-12-27
EP0578002A1 (de) 1994-01-12
IL106108A0 (en) 1993-10-20
HUT65190A (en) 1994-05-02
ZA934584B (en) 1994-02-01
CZ117493A3 (en) 1994-01-19
HU9301871D0 (en) 1993-09-28

Similar Documents

Publication Publication Date Title
TW231971B (OSRAM)
TW215421B (OSRAM)
DK0553875T3 (OSRAM)
FR2687601B1 (OSRAM)
IN176922B (OSRAM)
DK0576346T3 (OSRAM)
DK0596750T3 (OSRAM)
TW238337B (OSRAM)
DK0571874T3 (OSRAM)
TW257747B (OSRAM)
DK0571172T3 (OSRAM)
FR2688230B1 (OSRAM)
DK0597323T3 (OSRAM)
DE9209779U1 (OSRAM)
AU631518B2 (OSRAM)
AU2098792A (OSRAM)
IN177004B (OSRAM)
GB9205789D0 (OSRAM)
IN178766B (OSRAM)
IN179676B (OSRAM)
BR9304980A (OSRAM)
AU1844392A (OSRAM)
AU2138992A (OSRAM)
AU1862992A (OSRAM)
AU2840792A (OSRAM)